Searched for
ZYIL1
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Sometimes, ignoring all noise is the best option: 7 large-cap stocks from different sectors with an upside potential of up to 38%What is it that the street fears most when it comes to a slowdown or any other disruption (tariffs, or a sudden increase in commodity price...
- Nothing wrong in being bullish, if you know why & what you are doing: 7 large-cap stocks with an upside potential of 2 to 20%In the short term, what Trump says, the numbers from China, and what the US Fed does will determine stock prices. But in the long term, the...
- Best way to deal with volatility, just “ Hold” for wealth creation: 7 large-cap stocks with an upside potential of up to 41%If you are a long-term investor, your decisions cannot be based on what the Nifty or Sensex do every week, or even every quarter. So, if yo...
- One simple reason to own & trade them: 5 large-caps from different sectors with upside potential of up to 46%The rising stock price of a company does not mean that the business is strong. And a falling stock price does not mean that the business is...
- Zydus receives USFDA Orphan Drug Designation for Usnoflast to treat ALSZydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotr...
- Tailwinds and stronger balance sheets: 5 large-cap stocks with the right mix of two ratios & upside potential of up to 32%A crucial contribution to the growth of a business is the overall size of the market for its product or services. And by market size we mea...
- Why predict time and magnitude of correction, focus on business and diversification: 6 large-cap stocks with upside potential of up to 38%After a long time, probably after March 2024, stock prices and the indices have corrected in a very sharp manner – and across the board. Th...
- Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratiosThere are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to ...
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...
- Stocks in news: PB Fintech, ZEE, PVR Inox, KFin Tech, Mazagon DockZee Entertainment has sent a letter to Sony Group Corporation requesting an extension of the cutoff to complete the merger.
- Good for all market conditions: 6 largecap stocks with right mix of RoE & RoCEThere is sunshine all around, better than expected GDP numbers, further decline in oil prices, falling US bond yields and clear indication ...
- Tailwinds at the right time: 7 pharma stocks with an upside potential up to 37 %It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case o...
- Stocks in the news: TCS, IndiGo, Tata Power, ZEE, AB Fashion and Max VILRakesh Gangwal, co-founder of IndiGo, and his family are looking to sell a 2.8 per cent stake or 10.8 million shares in the budget carrier,...
- Zydus gets nod to conduct Phase II clinical study in patients with CAPS in AustraliaCAPS is a rare life-long auto-inflammatory condition, and is classified under orphan diseases. CAPS patients also experience multiple neuro...
- Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical...
- Zydus Cadila files investigational new drug application for COVID-19 treatmentDrug firm Zydus Cadila on Tuesday said it has filed the investigational new drug (IND) application for ZYIL1, positioned for management of ...
- Cadila Healthcare Q2 results: Net profit jumps over four-fold to Rs 473.4 crConsolidated total revenue from operations of the company stood at Rs 3,820 crore for the quarter under consideration. It was Rs 3,366.6 cr...
Load More
